@article{oai:repo.qst.go.jp:00044086,
 author = {Watanabe, Naoyuki and Oriuchi, Noboru and Tanada, Shuji and Murata, Hajime and Inoue, Tomio and Sasaki, Yasuhito and et.al and 渡辺 直行 and 棚田 修二 and 村田 啓 and 井上 登美夫 and 佐々木 康人},
 journal = {Nuklearmedizin},
 month = {},
 note = {Aim: The purpose of this study was to assess the potential for radioimmunodetection (RAID) of murine anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAb) F33-104 laveled with technetium-99m(99m-Tc) by a reduction-mediated labeling method.  Methods: The binding capacity of 99m-Tc-labeled anti-CEA MAb F33-104 with CEA by means of in vitro procedures such as immunoradiometric assay and cell binding assay and the biodistribution of 99m-Tc-labeled anti-CEA MAb F33-104 in normal nude mice and nude mice bearing human colon adenocarcinoma LS180 tumor were investigated and compared with 99m-Tc-labeled anti-CEA MAb BW431/26.  Results: The in vitro binding rate of 99m-Tc-labeled anti-CEA MAb F33-104 with CEA in solution and attached to the cell membrane was significantly higher than 99m-Tc-labeled anti-CEA MAb BW431/261 (31.4 0.95% vs. 11.9 0.55% at 100 ng/mL of solube CEA, 83.5 2.84% vs, 54.0 2.54% at 107 of LS 180 cells). In vivo, accumulation of 99m-Tc-labeled anti-CEA MAbF33-104 was higher at 18 h postinjection than 99m-Tc-labeled anti-CEA MAb BW431/26(20.1 3.50% ID/g vs. 14.4 3.30% ID/g). 99m-Tc-activity in the kidneys of nude mice bearing tumor was higher at 18 h postinjection than at 3 h (12.8 2.10% ID/g vs, 8.01 2.40% ID/g of 99m-Tc-labeled anti-CEA MAb F33-104, 10.7 1.70% ID/g vs. 8.10 1.75% ID/g of 99m-Tc-labeled anti-CEA MAb BW431/26). Conclusion: 99m-Tc-labeled anti-CEA MAb F33-104 is a potential novel agent for RAID of recurrent colorectal cancer.},
 pages = {115--119},
 title = {In Vitro and in Vivo Comparison of Binding of 99m-Tc-labeled Anti-CEA MAb F33-104 with 99m-Tc-labeled Anti-CEA MAb BW431/26},
 volume = {38},
 year = {1999}
}